Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

Media & Investor Release   Roche and Atea partner to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in Phase 2 clinical trials AT-527 has the potential to be the first novel oral antiviral to treat COVID-19 patients outside the hospital setting as well as in the hospital and may also be used in post-exposure

The International Twist

~ Davide Veglia With the COVID19 pandemic and the cancellation of many meetings and events, meeting planners are faced with the challenge of mitigating financial losses as well as maintaining brand fidelity with attendees. The entire travel service community is suffering and struggling to survive. Everyone involved: airlines, hotels, transportation, housing, exhibition, and registration companies

Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium

Media Release Basel, 18 November 2019 Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancer Follow-up data from pivotal phase III APHINITY study evaluating Perjeta plus Herceptin and chemotherapy in HER2-positive early breast cancer Results from phase III FeDeriCa study confirming the non-inferiority of a fixed-dose combination of Perjeta and Herceptin administered

Japan becomes the first country to approve Roche’s personalized medicine Rozlytrek

Media Release Basel, 18 June 2019 First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Phase II STARTRK-2 study showing that Rozlytrek shrank tumours in more than half of people with NTRK fusion-positive solid tumours, across 10